Get started
Author

Stojan Zavisic

Observed names: S. Zavisic, Zavisic, Stojan
Institution: Camurus AB (Sweden)
OpenAlex ID: A5087656804
Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations
2007 · Robert H. Dworkin, Dennis C. Turk, et al. · Journal of Pain · 3,460
Preferences for different treatment options among people living with acromegaly in the US
2024 · Jill Sisco, Mattias Furumalm, et al. · Current Medical Research and Opinion · 7
HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents
2020 · Joan Blade Creixenti, María-Victoria Mateos, et al. · Blood · 5
HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).
2020 · Maria-Victoria Mateos, Albert Oriol, et al. · Journal of Clinical Oncology · 5
The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone
2019 · Paul G. Richardson, Alessandra Larocca, et al. · Blood · 3
Real-world treatment patterns in relapsed/refractory multiple myeloma: Clinical and economic outcomes in patients treated with pomalidomide or daratumumab
2021 · Joshua Richter, Vamshi Ruthwik Anupindi, et al. · Journal of Oncology Pharmacy Practice · 2
Pf628 O-12-m1: an Evaluation of Time to Next Treatment in Melflufen and Dexamethasone-treated Patients With Relapsed/refractory Multiple Myeloma
2019 · S. Bringhen, P.G. Richardson, et al. · HemaSphere · 2
Cabazitaxel In Second Line (2l) Treatment Of Metastatic Castration Resistant Prostate Cancer : An Economic Evaluation In Sweden
2013 · F. Joulain, S. Zavisic, et al. · Value in Health · 2
PDF
Adverse event and outcome patterns in patients with advanced multiple myeloma in the United States.
2020 · Joshua Ryan Richter, Jason Yeaw, et al. · Journal of Clinical Oncology · 1
EE659 Societal and Economic Impact of Long-Acting Injectable Buprenorphine (LAIB) Compared With Standard Opioid Substitution Therapy (OST) in France
2025 · Mathieu Chappuy, Nicolas Petit, et al. · Value in Health
EPH73 Modelling the Wider Socio-Economic Costs of Problematic Opioid Use in Germany
2023 · G. Keel, S. Meyner, et al. · Value in Health
PDF
REALM (OP-RW001): Comparing the Characteristics and Clinical Outcomes of Patients with Relapsed/Refractory Multiple Myeloma in the Real World to Patients Receiving Melflufen in the Horizon Study
2021 · Sikander Ailawadhi, Ching-Kun Wang, et al. · Blood
MM-118: Adverse Event and Outcome Patterns in Patients with Advanced Multiple Myeloma in the US
2020 · Jason Yeaw, Vamshi Ruthwik Anupindi, et al. · Clinical Lymphoma Myeloma & Leukemia
Pcn78 Utilization and Costs Associated With Hospitalizations Among Adults With Relapsed and Refractory Multiple Myeloma in the Us
2020 · J. Yeaw, D. Shah, et al. · Value in Health
Quality of life of treatment for relapsed/refractory multiple myeloma: a systematic review
2019 · Maria Nassim, Jonas Nilsson, et al. · Clinical Lymphoma Myeloma & Leukemia
Pf726 Tolerability of Treatments for Relapsed/refractory Multiple Myeloma: a Systematic Review
2019 · M. Nassim, J. Nilsson, et al. · HemaSphere
Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).
2019 · Sara Bringhen, Paul G. Richardson, et al. · Journal of Clinical Oncology
Works count: 20
Citation count: 3,487
H-index: 4
I10-index: 1
Year
Topic
Type